Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1998 Oct 20;159(8):942–947.

Routine prenatal screening for HIV in a low-prevalence setting

D M Patrick 1, D M Money 1, J Forbes 1, S R Dobson 1, M L Rekart 1, D A Cook 1, P J Middleton 1, D R Burdge 1
PMCID: PMC1229739  PMID: 9834719

Abstract

BACKGROUND: The objectives of this study were to assess the effect of British Columbia's June 1994 guidelines for prenatal HIV screening on the rate of maternal-fetal HIV transmission and to estimate the cost-effectiveness of such screening. METHODS: The authors conducted a retrospective review of pregnancy and delivery statistics, HIV screening practices, laboratory testing volume, prenatal and labour management decisions of HIV-positive women, maternal-fetal transmission rates and associated costs. RESULTS: Over 1995 and 1996, 135,681 women were pregnant and 92,645 carried to term. The rate of HIV testing increased from 55% to 76% of pregnancies on chart review at one hospital between November 1995 and November 1996. On the basis of seroprevalence studies, an estimated 50.2 pregnancies and 34.3 (95% confidence interval 17.6 to 51.0) live births to HIV-positive women were expected. Of 42 identified mother-infant pairs with an estimated date of delivery during 1995 or 1996, 25 were known only through screening. Of these 25 cases, there were 10 terminations, 1 spontaneous abortion and 14 cases in which the woman elected to carry the pregnancy to term with antiretroviral therapy. There was one stillbirth. One instance of maternal-fetal HIV transmission occurred among the 13 live births. The net savings attributable to prevented infections among babies carried to term were $165,586, with a saving per prevented case of $75,266. INTERPRETATION: A routine offer of pregnancy screening for HIV in a low-prevalence setting reduces the rate of maternal-fetal HIV transmission and may rival other widely accepted health care expenditures in terms of cost-effectiveness.

Full Text

The Full Text of this article is available as a PDF (116.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbacci M. B., Dalabetta G. A., Repke J. T., Talbot B. L., Charache P., Polk B. F., Chaisson R. E. Human immunodeficiency virus infection in women attending an inner-city prenatal clinic: ineffectiveness of targeted screening. Sex Transm Dis. 1990 Jul-Sep;17(3):122–126. doi: 10.1097/00007435-199007000-00002. [DOI] [PubMed] [Google Scholar]
  2. Barnhart H. X., Caldwell M. B., Thomas P., Mascola L., Ortiz I., Hsu H. W., Schulte J., Parrott R., Maldonado Y., Byers R. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics. 1996 May;97(5):710–716. [PubMed] [Google Scholar]
  3. Brandeau M. L., Owens D. K., Sox C. H., Wachter R. M. Screening women of childbearing age for human immunodeficiency virus. A cost-benefit analysis. Arch Intern Med. 1992 Nov;152(11):2229–2237. [PubMed] [Google Scholar]
  4. Chang R. W., Pellisier J. M., Hazen G. B. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA. 1996 Mar 20;275(11):858–865. [PubMed] [Google Scholar]
  5. Cooper E. R., Nugent R. P., Diaz C., Pitt J., Hanson C., Kalish L. A., Mendez H., Zorrilla C., Hershow R., Moye J. After AIDS clinical trial 076: the changing pattern of zidovudine use during pregnancy, and the subsequent reduction in the vertical transmission of human immunodeficiency virus in a cohort of infected women and their infants. Women and Infants Transmission Study Group. J Infect Dis. 1996 Dec;174(6):1207–1211. doi: 10.1093/infdis/174.6.1207. [DOI] [PubMed] [Google Scholar]
  6. Coplan J., Dye T. D., Contello K. A., Cunningham C. K., Kirkwood K., Weiner L. B. Failure to identify human immunodeficiency virus-seropositive newborns: epidemiology and enrollment patterns in a predominantly white, nonurban setting. Pediatrics. 1995 Dec;96(6):1083–1089. [PubMed] [Google Scholar]
  7. Edelson J. T., Weinstein M. C., Tosteson A. N., Williams L., Lee T. H., Goldman L. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990 Jan 19;263(3):407–413. [PubMed] [Google Scholar]
  8. Fiscus S. A., Adimora A. A., Schoenbach V. J., Lim W., McKinney R., Rupar D., Kenny J., Woods C., Wilfert C. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA. 1996 May 15;275(19):1483–1488. [PubMed] [Google Scholar]
  9. Garner T. I., Dardis R. Cost-effectiveness analysis of end-stage renal disease treatments. Med Care. 1987 Jan;25(1):25–34. doi: 10.1097/00005650-198701000-00004. [DOI] [PubMed] [Google Scholar]
  10. Gorsky R. D., Farnham P. G., Straus W. L., Caldwell B., Holtgrave D. R., Simonds R. J., Rogers M. F., Guinan M. E. Preventing perinatal transmission of HIV--costs and effectiveness of a recommended intervention. Public Health Rep. 1996 Jul-Aug;111(4):335–341. [PMC free article] [PubMed] [Google Scholar]
  11. Hsia D. C., Fleishman J. A., East J. A., Hellinger F. J. Pediatric human immunodeficiency virus infection. Recent evidence on the utilization and costs of health services. Arch Pediatr Adolesc Med. 1995 May;149(5):489–496. doi: 10.1001/archpedi.1995.02170180019003. [DOI] [PubMed] [Google Scholar]
  12. Matheson P. B., Abrams E. J., Thomas P. A., Hernán M. A., Thea D. M., Lambert G., Krasinski K., Bamji M., Rogers M. F., Heagarty M. Efficacy of antenatal zidovudine in reducing perinatal transmission of human immunodeficiency virus type 1. The New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis. 1995 Aug;172(2):353–358. doi: 10.1093/infdis/172.2.353. [DOI] [PubMed] [Google Scholar]
  13. Mauskopf J. A., Paul J. E., Wichman D. S., White A. D., Tilson H. H. Economic impact of treatment of HIV-positive pregnant women and their newborns with zidovudine. Implications for HIV screening. JAMA. 1996 Jul 10;276(2):132–138. [PubMed] [Google Scholar]
  14. Mushlin A. I., Fintor L. Is screening for breast cancer cost-effective? Cancer. 1992 Apr 1;69(7 Suppl):1957–1962. doi: 10.1002/1097-0142(19920401)69:7+<1957::aid-cncr2820691716>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  15. Parrott R. H. Childhood human immunodeficiency virus infection: the spectrum of costs. J Acquir Immune Defic Syndr. 1991;4(2):122–129. [PubMed] [Google Scholar]
  16. Ratnam S., Hogan K., Hankins C. Prevalence of HIV infection among pregnant women in Newfoundland. CMAJ. 1996 Apr 1;154(7):1027–1032. [PMC free article] [PubMed] [Google Scholar]
  17. Remis R. S., Eason E. L., Palmer R. W., Najjar M., Leclerc P., Lebel F., Fauvel M. HIV infection among women undergoing abortion in Montreal. CMAJ. 1995 Nov 1;153(9):1271–1279. [PMC free article] [PubMed] [Google Scholar]
  18. Stephenson J. M., Griffioen A. The effect of HIV diagnosis on reproductive experience. Study Group for the Medical Research Council Collaborative Study of Women with HIV. AIDS. 1996 Dec;10(14):1683–1687. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES